{"id":8548,"date":"2024-02-22T10:18:00","date_gmt":"2024-02-22T02:18:00","guid":{"rendered":"https:\/\/flcube.com\/?p=8548"},"modified":"2024-11-24T18:21:35","modified_gmt":"2024-11-24T10:21:35","slug":"sinopharm-plans-to-privatize-china-traditional-medicine-holdings-in-a-usd-2-billion-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=8548","title":{"rendered":"Sinopharm Plans to Privatize China Traditional Medicine Holdings in a USD 2 Billion Deal"},"content":{"rendered":"\n<p>China Traditional Medicine Holdings (<a href=\"https:\/\/www.google.com\/finance\/quote\/0570:HKG\">HKG: 0570<\/a>; China TCM) has announced that its controlling shareholder, the state-owned Sinopharm Group Co., Ltd (HKG: 1099), intends to take the company private. The proposed deal values China TCM at a price of HKD 4.6 per share, representing a 34% premium over the recent closing price. The transaction, which involves 3.4 billion China TCM shares, will require a total cash outlay of approximately HKD 15.65 billion (USD 2.0 billion).<\/p>\n\n\n\n<p>This move to privatize China TCM comes amidst existing close business ties between Sinopharm and its subsidiary. As previously disclosed, these relationships encompass several areas, including the sale of certain drugs to Sinopharm, the procurement of traditional Chinese medicine (TCM) and chemical drug raw materials from Sinopharm, the provision of financial services by a Sinopharm member company, and the offering of commercial factoring services by another Sinopharm affiliate.<\/p>\n\n\n\n<p>The privatization deal underscores Sinopharm&#8217;s strategic commitment to China TCM and reflects the parent company&#8217;s intention to streamline operations and enhance shareholder value through a more centralized control over its traditional Chinese medicine business.- <a href=\"https:\/\/flcube.com\">Flcube.com<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China Traditional Medicine Holdings (HKG: 0570; China TCM) has announced that its controlling shareholder, the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1486,1485,20,1484,945,2311],"class_list":["post-8548","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-china-tcm","tag-china-traditional-medicine","tag-finance","tag-hkg-0570","tag-hkg-1099","tag-sinopharm-group-company"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sinopharm Plans to Privatize China Traditional Medicine Holdings in a USD 2 Billion Deal - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China Traditional Medicine Holdings (HKG: 0570; China TCM) has announced that its controlling shareholder, the state-owned Sinopharm Group Co., Ltd (HKG: 1099), intends to take the company private. The proposed deal values China TCM at a price of HKD 4.6 per share, representing a 34% premium over the recent closing price. The transaction, which involves 3.4 billion China TCM shares, will require a total cash outlay of approximately HKD 15.65 billion (USD 2.0 billion).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=8548\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sinopharm Plans to Privatize China Traditional Medicine Holdings in a USD 2 Billion Deal\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=8548\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-02-22T02:18:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-24T10:21:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8548#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8548\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sinopharm Plans to Privatize China Traditional Medicine Holdings in a USD 2 Billion Deal\",\"datePublished\":\"2024-02-22T02:18:00+00:00\",\"dateModified\":\"2024-11-24T10:21:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8548\"},\"wordCount\":187,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"China TCM\",\"China Traditional Medicine\",\"Finance\",\"HKG: 0570\",\"HKG: 1099\",\"Sinopharm Group Company\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=8548#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8548\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=8548\",\"name\":\"Sinopharm Plans to Privatize China Traditional Medicine Holdings in a USD 2 Billion Deal - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-02-22T02:18:00+00:00\",\"dateModified\":\"2024-11-24T10:21:35+00:00\",\"description\":\"China Traditional Medicine Holdings (HKG: 0570; China TCM) has announced that its controlling shareholder, the state-owned Sinopharm Group Co., Ltd (HKG: 1099), intends to take the company private. The proposed deal values China TCM at a price of HKD 4.6 per share, representing a 34% premium over the recent closing price. The transaction, which involves 3.4 billion China TCM shares, will require a total cash outlay of approximately HKD 15.65 billion (USD 2.0 billion).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8548#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=8548\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8548#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sinopharm Plans to Privatize China Traditional Medicine Holdings in a USD 2 Billion Deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sinopharm Plans to Privatize China Traditional Medicine Holdings in a USD 2 Billion Deal - Insight, China&#039;s Pharmaceutical Industry","description":"China Traditional Medicine Holdings (HKG: 0570; China TCM) has announced that its controlling shareholder, the state-owned Sinopharm Group Co., Ltd (HKG: 1099), intends to take the company private. The proposed deal values China TCM at a price of HKD 4.6 per share, representing a 34% premium over the recent closing price. The transaction, which involves 3.4 billion China TCM shares, will require a total cash outlay of approximately HKD 15.65 billion (USD 2.0 billion).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=8548","og_locale":"en_US","og_type":"article","og_title":"Sinopharm Plans to Privatize China Traditional Medicine Holdings in a USD 2 Billion Deal","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=8548","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-02-22T02:18:00+00:00","article_modified_time":"2024-11-24T10:21:35+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=8548#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=8548"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sinopharm Plans to Privatize China Traditional Medicine Holdings in a USD 2 Billion Deal","datePublished":"2024-02-22T02:18:00+00:00","dateModified":"2024-11-24T10:21:35+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=8548"},"wordCount":187,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["China TCM","China Traditional Medicine","Finance","HKG: 0570","HKG: 1099","Sinopharm Group Company"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=8548#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=8548","url":"https:\/\/flcube.com\/?p=8548","name":"Sinopharm Plans to Privatize China Traditional Medicine Holdings in a USD 2 Billion Deal - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-02-22T02:18:00+00:00","dateModified":"2024-11-24T10:21:35+00:00","description":"China Traditional Medicine Holdings (HKG: 0570; China TCM) has announced that its controlling shareholder, the state-owned Sinopharm Group Co., Ltd (HKG: 1099), intends to take the company private. The proposed deal values China TCM at a price of HKD 4.6 per share, representing a 34% premium over the recent closing price. The transaction, which involves 3.4 billion China TCM shares, will require a total cash outlay of approximately HKD 15.65 billion (USD 2.0 billion).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=8548#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=8548"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=8548#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sinopharm Plans to Privatize China Traditional Medicine Holdings in a USD 2 Billion Deal"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/8548","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=8548"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/8548\/revisions"}],"predecessor-version":[{"id":8549,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/8548\/revisions\/8549"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=8548"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=8548"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=8548"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}